Company News

Share this article:
Eli Lilly is trimming its osteoporosis, diabetes and neurosciences sales forces by a total of 191 jobs as part of a restructuring plan announced in September, Indianapolis Business Journal reports. The company intends to lay off 5,500 by 2011 in an effort to soften the blow when Zyprexa, which has $4.7 billion in global sales, goes off patent the same year.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.